Viewing Study NCT04265534


Ignite Creation Date: 2025-12-25 @ 2:31 AM
Ignite Modification Date: 2025-12-26 @ 1:07 AM
Study NCT ID: NCT04265534
Status: TERMINATED
Last Update Posted: 2022-09-21
First Post: 2020-02-07
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
Sponsor: Calithera Biosciences, Inc
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module